
Rationale. Dermoscopy is the gold standard for the non-invasive diagnosis of skin tumors. However, the lack of standardized Russian-language terminology has to date created barriers to interdisciplinary collaboration and reduced the effectiveness of early melanoma detection and patient monitoring. Adapting the dermoscopic terms established by the International Dermoscopy Society (IDS) in 2016 into Russian, followed by expert validation, is a crucial task for ensuring the reproducibility of diagnostic descriptions, improving the system of continuing medical and pharmaceutical education, and enhancing the quality of specialized medical care in the Russian Federation. Objective. To develop and validate a Russian-language version of standardized dermoscopic terminology through expert consensus in order to improve the quality of skin tumor diagnosis and enhance continuing professional education in the Russian Federation. Methods. A consensus vote was performed using the modified Delphi method, involving an expert panel of dermatovenereologists and oncologists who utilize dermoscopy in clinical practice. In this regard, a multidisciplinary collaboration has been established between the Russian Medical Academy of Continuing Professional Education (RMACPE) and the State Research Center of Dermatovenereology and Cosmetology (SRCDC) on one side, and the Russian Society of Dermatovenereologists and Cosmetologists (RSDVC), the Association of Oncologists of Russia (AOR), the National Alliance of Dermatovenereologists and Cosmetologists (NADC), and the Russian Melanoma Professional Association (Melanoma.PRO) on the other. A standardized questionnaire was developed for expert evaluation, comprising a translated English term, a schematic representation, a definition, a histopathological correlation, and the clinical significance of each dermoscopic feature. The study was carried out using the modified Delphi method between December 15, 2025, and February 15, 2026. The preliminary stage involved forming a working group to define the scope of consensus, developing statements, and pilot-testing the questionnaire for anonymous expert voting. The questionnaire included 67 dermoscopic terms with adapted translations, schematic images, definitions, histological correlations, and lists of pathologies in which these signs most frequently occur. Statistical analysis involved calculating absolute and relative values, followed by stratification by specialty. Consensus was defined as at least 70% agreement. Inter-rater consistency was assessed using a consensus coefficient, while expert engagement was measured by a proposal index. Alternative terms proposed by the experts underwent a frequency analysis of distinct wording variants. The comments were qualitatively classified into the following categories: linguistic clarifications, clinical remarks, and recommendations for the standardization of dermoscopic terms. Results. The evaluation of standardized dermoscopic terms in Russian was conducted. A total of 67 specialists participated in the vote: 48 dermatovenereologists (71.6%), 16 oncologists (23.9%), and 3 clinicians (4.5%) who indicated dual specialties (dermatovenereology and oncology). The quantitative and qualitative analyses were performed on the alternative terms and comments proposed by the expert council members. The expert feedback was categorized into two groups: linguistic and clinical. Statistical analysis revealed a high degree of inter-rater agreement: the consensus coefficient was 0.84 for oncologists and 0.82 for dermatovenereologists. All proposed terms met or exceeded the established consensus threshold of 70%, fully complying with international consensus standards. Thus, the voting process demonstrated that experts successfully reached a consensus on all terms submitted for validation (Tables 1—5). Conclusion. The national consensus on dermoscopy provides a methodological basis for standardizing dermoscopic diagnosis in Russia. Unified terminology ensures consistency in research protocols, increases the reproducibility of findings, and improves interdisciplinary collaboration. The integration of this consensus into the daily clinical practice of interested medical specialists and continuing medical and pharmaceutical education will primarily contribute to reducing diagnostic errors in skin tumors, thereby helping to achieve the national healthcare system goal of increasing life expectancy.
Irina Markovna Korsunskaya was born in 1948 in Kharkiv. In 1974, she graduated from the N. I. Pirogov 2nd Moscow State Medical Institute (awarded the Order of Lenin), specializing in pediatrics. Following her graduation, she completed an internship and qualified as a dermatovenereologist; subsequently, from 1977 to 1979, she pursued a residency in skin and venereal diseases at the Central Institute for Advanced Medical Studies (TsOLIUV).
Background. Pharmacoeconomic studies serve as a scientific basis for optimizing healthcare delivery and assessing the economic feasibility of various therapeutic approaches. Objective. To perform a comparative assessment of the pharmacoeconomic effectiveness of treating patients with uncomplicated gonococcal, chlamydial, and M. genitalium (MG) infections as well as trichomoniasis, according to either a personalized algorithm (PA) or clinical guidelines (CGs). Materials and methods. Patients (n=508) with uncomplicated gonococcal (n=175), chlamydial (n=195), and MG (n=111) infections, as well as trichomoniasis (n=27), received outpatient treatment at the Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology (MSPCDC) in 2024. Group 1 included 286 patients who underwent treatment according to the PA depending on the concentration of pathogen DNA in the urogenital tract (UGT): higher doses and longer courses of antimicrobial agents for high pathogen DNA concentrations (>104 GE/mL), and lower doses and shorter courses for low DNA concentrations (<104 GE/mL). Patients in Group 2 (n=222) were treated in accordance with the 2024 CGs (without regard to pathogen DNA concentration in the urogenital tract). The DNA was analyzed using real-time PCR. Cost-effectiveness ratio (CER) and incremental cost-effectiveness ratio (ICER) were used to evaluate treatment and associated costs. Results. It was established that the PA of therapy, which is based on DNA concentration levels in UGT samples, was both clinically and economically more effective than the approach according to the CGs for gonococcal, chlamydial, and MG infections. The CER values for therapy using the PA were lower than those for treatment according to the CGs (37.8 vs. 38.5 for gonococcal infection, 36.7 vs. 42.6 for chlamydial infection, and 44.1 vs. 66.3 for MG infection), demonstrating the economic efficiency of the proposed PA, given that the treatment regimen with the lowest CER value is economically preferable. For chlamydial and MG infections, the PA-based strategy proved to be both less costly and more effective than the CG-based one (ICER: –77.4 for C. trachomatis and –104.08 for MG infection). No pharmacoeconomic benefits were demonstrated for the treatment of uncomplicated trichomoniasis using the PA. Conclusion. The PA, which considers DNA concentrations in the UGT, was found to offer a pharmacoeconomic advantage over standard therapy based on CGs. This advantage was most pronounced in cases of chlamydial and MG infections.
Larva migrans is a common parasitic disease in tropical and subtropical countries. The cutaneous form of the disease is caused by the larvae of canine and feline hookworms (Ancylostoma caninum, A. brasiliense, and A. ceylonicum). Human infection occurs through skin contact with moist, sandy soil contaminated with animal feces. With growing tourist interest in Southwest and Southeast Asia, Africa and South America, clinicians are more likely to encounter patients seeking treatment for cutaneous helminthiasis after visiting endemic regions. This requires dermatovenereologists to obtain a detailed travel history and carefully assess clinical manifestations for diagnosis and timely treatment of the disease. We present a clinical case of cutaneous larva migrans in a resident of the Sverdlovsk region after a vacation in the Republic of the Philippines and Türkiye. The report covers the medical history, epidemiological features, and an unusual presentation localized on the skin of the right buttock, as well as pathomorphological skin biopsy findings and the specific treatment regimen. We would like to highlight the patient’s complex diagnostic pathway. Specific therapy with albendazole (400 mg/day for 7 days) resulted in complete resolution of the skin lesions.
Vitiligo is classified as an acquired hypomelanosis with a genetic predisposition to autoimmune reactions. The disease presents with focal depigmentation. Vitiligo is often mistakenly regarded as a cosmetic defect, and proper examination and treatment are neglected. The clinical manifestations of the disease have a significant impact on patients’ quality of life. This article is devoted to a comprehensive analysis of the psychosocial aspects of vitiligo and their impact on patients’ quality of life. In addition to investigating the etiology, pathogenesis, and clinical manifestations of the disease, the psychological status and quality of life of patients are considered in detail. Particular attention is paid to factors determining the degree of quality of life impairment in vitiligo, including gender differences, age, lesion location, and the patient’s socioeconomic status. It has been established that the presence of depigmentation lesions on exposed areas of the body significantly exacerbates the psychological burden of the disease and impedes patients’ social adaptation. The results of large international studies, demonstrating the significant impact of vitiligo on the emotional state and social adaptation of patients, are presented. This article highlights the need for a comprehensive approach to vitiligo management, including not only dermatological but also psychological support. The findings can be used to develop effective treatment and support strategies for patients with vitiligo.